Alzheimer's Association
Five Things We Learned About Alzheimer’s Disease in 2025
—– Alzheimer’s Association San Diego & Imperial Chapter Highlights Important Advances
Made This Year and What They Mean to Local Families —–
Dec 1, 2025 — This year marked a turning point in Alzheimer’s disease research, with major strides in diagnostics, treatment options and public understanding of cognitive health. Here are five key developments from 2025:
Structured Lifestyle Program Boosts Cognition in At-Risk Older Adults
The Alzheimer’s Association’s U.S. POINTER study revealed that both structured and self-guided lifestyle interventions improved cognitive function over two years in older adults at risk for decline. Participants in the structured group — who engaged in regular coaching and peer support sessions focused on exercise, nutrition, cognitive training and health monitoring — showed significantly higher gains. These benefits were consistent across populations, underscoring the program’s potential for broad public health impact.
Conducted at five sites nationwide with more than 2,100 participants, the study demonstrated high retention and engagement. The Alzheimer’s Association, which has invested nearly $90 million in the study, will continue working with participants for at least four more years and explore a variety of local programs to implement the U.S. POINTER lifestyle “recipe.”
Building on this momentum, the Association will launch new initiatives, including a personal brain health web-based tool and a virtual training program for health care providers.
FDA Clears First-Ever Blood Tests for Alzheimer’s
In a landmark advancement, the U.S. Food and Drug Administration (FDA) cleared two blood tests for Alzheimer’s disease in 2025.
In May, the FDA cleared the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test, which detects amyloid plaques — a hallmark of Alzheimer’s — in adults 50 and older with symptoms. While not a standalone diagnostic tool, it offers a less invasive option to support diagnosis. The Alzheimer’s Association has developed clinical guidelines to help specialists determine appropriate use.
In October, the FDA cleared the Elecsys pTau181 plasma test for use in primary care. Approved for adults 55 and older with cognitive symptoms, the test helps rule out Alzheimer’s-related brain changes and may reduce the need for PET scans or spinal taps in certain clinical settings. The Association emphasizes that diagnosis remains a multi-step process and urges providers to use blood biomarker tests alongside established “gold standard” tests, clinical judgment and evolving guidelines.
Survey: Most Americans Want Early Alzheimer’s Diagnosis
A nationwide survey conducted by the Alzheimer’s Association in 2025 found that nearly 4 in 5 Americans (79%) aged 45 and older want to know if they have Alzheimer’s before symptoms impact their lives. Additionally, 91% said they would take a simple test — such as a blood biomarker test — if available.
Nearly 3 in 5 respondents (58%) said they would accept a moderate or high level of risk from a medication that could slow the disease’s progression.
“Our survey shows that people want to know if they have Alzheimer’s — and they want to know early,” said Elizabeth Edgerly, Ph.D., senior director of Community Programs and Services at the Alzheimer’s Association. “They’re eager for simple tests and early access to care, including treatments that can slow progression. This underscores the importance of making diagnostic testing widely available.”
FDA Approves Weekly At-Home Dosing for Alzheimer’s Treatment
In August, the FDA approved a new delivery method for Leqembi, a treatment for early Alzheimer’s. Patients who complete the initial 18-month intravenous (IV) regimen can now receive weekly subcutaneous injections at home using an autoinjector.
This change may ease the burden on patients and caregivers by reducing travel and simplifying treatment. Studies show that continued use of Leqembi helps preserve memory and thinking skills, with side effects remaining stable or improving after the first year.
The Alzheimer’s Association encourages participation in ALZ-NET, a program collecting real-world data on Alzheimer’s treatments. This information will help improve care, support research and ensure equitable access to effective therapies.
ALZPro Launches to Support Dementia Professionals
In 2025, the Alzheimer’s Association launched ALZPro, a centralized online hub offering clinical guidelines, training, research publications and practical tools for professionals advancing dementia research and care.
Designed to empower researchers, clinicians and care providers, ALZPro delivers timely, evidence-based resources to support high quality, person-centered care. The platform helps professionals stay current with breakthroughs in science and treatment while addressing the evolving needs of diverse populations.
ALZPro unites trusted resources in one accessible location, supporting professionals in translating research into practice and improving outcomes across all stages of the disease.
“This year ushered in groundbreaking progress in Alzheimer’s research — from earlier, more accessible diagnosis to innovative treatments offering hope to millions. The Alzheimer’s Association remains committed to accelerating these advances and ensuring every community benefits from improved care and science.” — Janet Hamada-Kelley, Executive Director, Alzheimer’s Association San Diego & Imperial Chapter
About the Alzheimer's Association
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.
CONTACT: Eric Thompson, 858-472-1902, elthompson@alz.org
